Sumitomo Applies for Approval of iPS Cell Therapy for Parkinson’s Disease

Published in The Japan Times

Sumitomo Pharma has applied for regulatory approval in Japan to market a cell therapy that transplants dopamine neuron precursors into the brains of Parkinson’s patients using iPS cells. The therapy, developed with Kyoto University, showed safety and symptom improvement in a phase 1 trial involving seven patients monitored for two years. No serious adverse events were reported, and four participants saw meaningful improvements. The iPS cells were derived from healthy donors and reprogrammed to restore dopamine-producing neurons, offering a regenerative approach beyond symptom management.

Read the full article on Japan Times:

👉 Drugmaker in Japan seeks approval for stem cell treatment for Parkinson's

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.